{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:59:48Z","timestamp":1788314388696,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T00:00:00Z","timestamp":1611360000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T00:00:00Z","timestamp":1611360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Surg"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gallbladder cancer is a rare but highly malignant cancer, which often progresses to a metastatic stage when diagnosed because of its asymptomatic manifestation. In this study, we intended to analyze the prognostic value of metastatic gallbladder adenocarcinoma (GBA) with site-specific metastases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using the Surveillance, Epidemiology, and End Results (SEER) database, GBA patients diagnosed with metastases between 2010 and 2016 were selected to identify the prognosis according to the isolated metastatic sites, including liver, lung, bone, brain and distant lymph nodes (DL). Kaplan\u2013Meier methods were used for survival comparisons and multivariable Cox regression models were constructed to find out independent factors that associated with survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data from 1526 eligible patients were extracted from the SEER database. Among the patients, 788 (51.6%) had isolated liver metastases, 80 (5.2%) had isolated distant nodal involvement, 45 (2.9%) had isolated lung metastases, 21 (1.4%) had isolated bone metastases, 2 (0.1%) had isolated brain metastases and 590 (38.7%) had multiple metastases. No significant survival difference was shown between patients with single or multisite metastases (P\u2009&gt;\u20090.05). Patients with isolated lung or DL metastases had significant better survival outcomes than those with isolated bone metastases (P\u2009&lt;\u20090.05). Multivariate analysis showed that performing surgery at primary site, receiving chemotherapy were associated with better OS and CSS for patients with isolated liver or DL metastases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The study showed that different metastatic sites affect survival outcomes in metastatic GBA patients. Highly selected subset of patients with liver or DL metastases might benefit from surgery at primary site.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12893-021-01068-8","type":"journal-article","created":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T03:02:59Z","timestamp":1611370979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Site-specific metastases of gallbladder adenocarcinoma and their prognostic value for survival: a SEER-based study"],"prefix":"10.1186","volume":"21","author":[{"given":"Yingnan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuolong","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chentao","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajie","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouzhang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7718-2805","authenticated-orcid":false,"given":"Jinfu","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,23]]},"reference":[{"issue":"1","key":"1068_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7\u201334.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1068_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CEJ.0000000000000402","volume":"28","author":"V Jaruvongvanich","year":"2019","unstructured":"Jaruvongvanich V, Yang JD, Peeraphatdit T, et al. The incidence rates and survival of gallbladder cancer in the USA. Eur J Cancer Prev. 2019;28(1):1\u20139.","journal-title":"Eur J Cancer Prev"},{"key":"1068_CR3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jss.2018.04.067","volume":"230","author":"AJ Lee","year":"2018","unstructured":"Lee AJ, Chiang YJ, Lee JE, et al. Validation of American Joint Committee on Cancer eighth staging system for gallbladder cancer and its lymphadenectomy guidelines. J Surg Res. 2018;230:148\u201354.","journal-title":"J Surg Res"},{"issue":"6","key":"1068_CR4","doi-asserted-by":"publisher","first-page":"e0198809","DOI":"10.1371\/journal.pone.0198809","volume":"13","author":"S Samuel","year":"2018","unstructured":"Samuel S, Mukherjee S, Ammannagari N, et al. Clinicopathological characteristics and outcomes of rare histologic subtypes of gallbladder cancer over two decades: a population-based study. PLoS ONE. 2018;13(6):e0198809.","journal-title":"PLoS ONE"},{"key":"1068_CR5","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3389\/fonc.2019.00409","volume":"9","author":"Z Wang","year":"2019","unstructured":"Wang Z, Li Y, Jiang W, et al. Simple cholecystectomy is adequate for patients with t1b gallbladder adenocarcinoma < 1 cm in diameter. Front Oncol. 2019;9:409.","journal-title":"Front Oncol"},{"issue":"2","key":"1068_CR6","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.suc.2018.12.008","volume":"99","author":"L Hickman","year":"2019","unstructured":"Hickman L, Contreras C. Gallbladder cancer: diagnosis, surgical management, and adjuvant therapies. Surg Clin N Am. 2019;99(2):337\u201355.","journal-title":"Surg Clin N Am"},{"issue":"4","key":"1068_CR7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/SLA.0000000000002385","volume":"266","author":"GG Kasumova","year":"2017","unstructured":"Kasumova GG, Tabatabaie O, Najarian RM, et al. Surgical management of gallbladder cancer: simple versus extended cholecystectomy and the role of adjuvant therapy. Ann Surg. 2017;266(4):625\u201331.","journal-title":"Ann Surg"},{"issue":"15","key":"1068_CR8","doi-asserted-by":"publisher","first-page":"4620","DOI":"10.3748\/wjg.v21.i15.4620","volume":"21","author":"X-D He","year":"2015","unstructured":"He X-D, Li J-J, Liu W, et al. Surgical procedure determination based on tumor-node-metastasis staging of gallbladder cancer. World J Gastroenterol. 2015;21(15):4620\u20136.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"1068_CR9","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/cam4.1044","volume":"6","author":"R Rahman","year":"2017","unstructured":"Rahman R, Simoes EJ, Schmaltz C, et al. Trend analysis and survival of primary gallbladder cancer in the United States: a 1973\u20132009 population-based study. Cancer Med. 2017;6(4):874\u201380.","journal-title":"Cancer Med"},{"issue":"3","key":"1068_CR10","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1245\/s10434-014-4044-4","volume":"22","author":"DJ Birnbaum","year":"2015","unstructured":"Birnbaum DJ, Vigano L, Russolillo N, et al. Lymph node metastases in patients undergoing surgery for a gallbladder cancer. Extension of the lymph node dissection and prognostic value of the lymph node ratio. Ann Surg Oncol. 2015;22(3):811\u20138.","journal-title":"Ann Surg Oncol"},{"key":"1068_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.11604\/pamj.2018.31.52.14630","volume":"31","author":"M Essarghini","year":"2018","unstructured":"Essarghini M, Bounaim A. Metastases in trocar sites secondary to gallbladder adenocarcinoma. Pan Afr Med J. 2018;31:52.","journal-title":"Pan Afr Med J"},{"issue":"4","key":"1068_CR12","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/CCO.0b013e3283620fd8","volume":"25","author":"MG McNamara","year":"2013","unstructured":"McNamara MG, Metran-Nascente C, Knox JJ. State-of-the-art in the management of locally advanced and metastatic gallbladder cancer. Curr Opin Oncol. 2013;25(4):425\u201331.","journal-title":"Curr Opin Oncol"},{"issue":"7747","key":"1068_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41586-019-1004-y","volume":"567","author":"JW Lee","year":"2019","unstructured":"Lee JW, Stone ML, Porrett PM, et al. Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature. 2019;567(7747):249\u201352.","journal-title":"Nature"},{"issue":"2","key":"1068_CR14","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s13277-015-4557-x","volume":"37","author":"S Azizidoost","year":"2016","unstructured":"Azizidoost S, Ahmadzadeh A, Seghatoleslami M, et al. Hepatic metastatic niche: from normal to pre-metastatic and metastatic niche. Tumour Biol. 2016;37(2):493\u2013503.","journal-title":"Tumour Biol"},{"issue":"10","key":"1068_CR15","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.3748\/wjg.v23.i10.1872","volume":"23","author":"H Oweira","year":"2017","unstructured":"Oweira H, Petrausch U, Helbling D, et al. Prognostic value of site-specific metastases in pancreatic adenocarcinoma: A Surveillance Epidemiology and End Results database analysis. World J Gastroenterol. 2017;23(10):1872\u201380.","journal-title":"World J Gastroenterol"},{"issue":"18","key":"1068_CR16","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.2217\/fon-2018-0846","volume":"15","author":"X Yan","year":"2019","unstructured":"Yan X, Wang P, Zhu Z, et al. Site-specific metastases of intrahepatic cholangiocarcinoma and its impact on survival: a population-based study. Future Oncol (Lond, Engl). 2019;15(18):2125\u201337.","journal-title":"Future Oncol (Lond, Engl)"},{"issue":"4","key":"1068_CR17","doi-asserted-by":"publisher","first-page":"403","DOI":"10.14701\/ahbps.2019.23.4.403","volume":"23","author":"M Prieto","year":"2019","unstructured":"Prieto M, Gastaca M, Ruiz P, et al. Long term recurrence free survival in a stage IV gallbladder cancer treated with chemotherapy plus trastuzumab and salvage liver resection. Ann Hepatobiliary Pancreat Surg. 2019;23(4):403\u20137.","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"issue":"7","key":"1068_CR18","doi-asserted-by":"publisher","first-page":"djw324","DOI":"10.1093\/jnci\/djw324","volume":"109","author":"T Mitin","year":"2017","unstructured":"Mitin T, Enestvedt CK, Jemal A, et al. Limited use of adjuvant therapy in patients with resected gallbladder cancer despite a strong association with survival. J Natl Cancer Inst. 2017;109(7):djw324.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"1068_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejso.2018.08.020","volume":"45","author":"AR Hakeem","year":"2019","unstructured":"Hakeem AR, Papoulas M, Menon KV. The role of neoadjuvant chemotherapy or chemoradiotherapy for advanced gallbladder cancer\u2014a systematic review. Eur J Surg Oncol. 2019;45(2):83\u201391.","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"1068_CR20","doi-asserted-by":"publisher","first-page":"djw202","DOI":"10.1093\/jnci\/djw202","volume":"109","author":"KC Mantripragada","year":"2017","unstructured":"Mantripragada KC, Hamid F, Shafqat H, et al. Adjuvant therapy for resected gallbladder cancer: analysis of the national cancer data base. J Natl Cancer Inst. 2017;109(2):djw202.","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"1068_CR21","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1200\/JCO.2007.14.7934","volume":"26","author":"SJ Wang","year":"2008","unstructured":"Wang SJ, Fuller CD, Kim J-S, et al. Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer. J Clin Oncol. 2008;26(13):2112\u20137.","journal-title":"J Clin Oncol"},{"issue":"35","key":"1068_CR22","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.1200\/JCO.2010.33.8020","volume":"29","author":"SJ Wang","year":"2011","unstructured":"Wang SJ, Lemieux A, Kalpathy-Cramer J, et al. Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol. 2011;29(35):4627\u201332.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1068_CR23","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1586\/egh.10.45","volume":"4","author":"J Weigt","year":"2010","unstructured":"Weigt J, Malfertheiner P. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. Expert Rev Gastroenterol Hepatol. 2010;4(4):395\u20137.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"1068_CR24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.6004\/jnccn.2017.7067","volume":"16","author":"V Verma","year":"2018","unstructured":"Verma V, Surkar SM, Brooks ED, et al. Chemoradiotherapy versus chemotherapy alone for unresected nonmetastatic gallbladder cancer: national practice patterns and outcomes. J Natl Compr Cancer Netw. 2018;16(1):59\u201365.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"10","key":"1068_CR25","first-page":"3156","volume":"8","author":"A Rashid","year":"2002","unstructured":"Rashid A, Ueki T, Gao YT, et al. K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. Clin Cancer Res. 2002;8(10):3156\u201363.","journal-title":"Clin Cancer Res"},{"key":"1068_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1837774","author":"A Rizzo","year":"2020","unstructured":"Rizzo A, Ricci AD, Bonucci C, et al. Experimental HER2 targeted therapies for biliary tract cancer. Expert Opin Investig Drugs. 2020. https:\/\/doi.org\/10.1080\/13543784.2021.1854724 (Epub ahead of print).","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"1068_CR27","doi-asserted-by":"publisher","first-page":"430","DOI":"10.21037\/jgo.2017.05.04","volume":"8","author":"DY Zhao","year":"2017","unstructured":"Zhao DY, Lim KH. Current biologics for treatment of biliary tract cancers. J Gastrointest Oncol. 2017;8(3):430\u201340.","journal-title":"J Gastrointest Oncol"},{"issue":"8","key":"1068_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11864-020-00767-3","volume":"21","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi JD, Shroff RT. New treatment options for advanced biliary tract cancer. Curr Treat Options Oncol. 2020;21(8):63.","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"1068_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1\u201310.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1068_CR30","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1007\/s00535-020-01712-9","volume":"55","author":"C Xie","year":"2020","unstructured":"Xie C, McGrath NA, Monge Bonilla C, et al. Systemic treatment options for advanced biliary tract carcinoma. J Gastroenterol. 2020;55(10):944\u201357.","journal-title":"J Gastroenterol"},{"issue":"4","key":"1068_CR31","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.eururo.2014.05.034","volume":"66","author":"DY Heng","year":"2014","unstructured":"Heng DY, Wells JC, Rini BI, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2014;66(4):704\u201310.","journal-title":"Eur Urol"},{"issue":"6","key":"1068_CR32","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00423-015-1323-x","volume":"400","author":"FJ Huttner","year":"2015","unstructured":"Huttner FJ, Schneider L, Tarantino I, et al. Palliative resection of the primary tumor in 442 metastasized neuroendocrine tumors of the pancreas: a population-based, propensity score-matched survival analysis. Langenbeck\u2019s Arch Surg. 2015;400(6):715\u201323.","journal-title":"Langenbeck's Arch Surg"},{"issue":"1","key":"1068_CR33","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.surg.2015.05.042","volume":"159","author":"XM Keutgen","year":"2016","unstructured":"Keutgen XM, Nilubol N, Glanville J, et al. Resection of primary tumor site is associated with prolonged survival in metastatic nonfunctioning pancreatic neuroendocrine tumors. Surgery. 2016;159(1):311\u20138.","journal-title":"Surgery"},{"issue":"10","key":"1068_CR34","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1056\/NEJMms1902657","volume":"381","author":"J DelFattore","year":"2019","unstructured":"DelFattore J. Death by stereotype? Cancer treatment in unmarried patients. New Engl J Med. 2019;381(10):982\u20135.","journal-title":"New Engl J Med"}],"container-title":["BMC Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12893-021-01068-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12893-021-01068-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12893-021-01068-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T03:11:25Z","timestamp":1611371485000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcsurg.biomedcentral.com\/articles\/10.1186\/s12893-021-01068-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,23]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1068"],"URL":"https:\/\/doi.org\/10.1186\/s12893-021-01068-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-76624\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-76624\/v2","asserted-by":"object"}]},"ISSN":["1471-2482"],"issn-type":[{"value":"1471-2482","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,23]]},"assertion":[{"value":"12 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was waived by Ethics Committee of First Affiliated Hospital of Wenzhou Medical University, as SEER data is publicly available and without specific identifiers.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}